!DOCTYPE HTML>
Research on Drug Use in Obese Patients (1013)
Source: Council on Therapeutics
To encourage drug product manufacturers to conduct pharmacokinetic and pharmacodynamic research in obese patients to facilitate safe and effective dosing of medications in this patient population, especially for medications most likely to be affected by obesity; further,
To encourage manufacturers to include in the Food and Drug Administration (FDA)-approved labeling detailed information on characteristics of individuals enrolled in drug dosing studies; further,
To advocate that the FDA develop guidance for the design and reporting of studies that support dosing recommendations in obese patients; further,
To advocate for increased enrollment of obese patients in preapproval clinical trials of new medications; further,